Life years and secondary outcomes from the model
| Drug | Mean (95% credible interval) | |||||
|---|---|---|---|---|---|---|
| Life years* | Life expectancy, yr | Major stroke, cumulative % | Major bleed, cumulative % | Time off medication per patient, mo | Bed-bound, cumulative % | |
| Acetylsalicylic acid | 6.25 (6.24 to 6.26) | 84.4 (84.4 to 84.5) | 26.9 (26.7 to 27.0) | 14.2 (14.1 to 14.2) | 1.12 (1.12 to 1.13) | 5.2 (5.2 to 5.3) |
| Warfarin | 6.61 (6.60 to 6.62) | 84.7 (84.7 to 84.7) | 14.4 (14.4 to 14.5) | 25.5 (25.4 to 25.5) | 2.04 (2.03 to 2.04) | 3.2 (3.2 to 3.2) |
| Apixaban, 5 mg | 7.36 (7.35 to 7.37) | 85.5 (85.5 to 85.5) | 12.9 (12.9 to 13.1) | 19.4 (19.4 to 19.5) | 1.57 (1.56 to 1.57) | 2.7 (2.7 to 2.7) |
| Edoxaban, 30 mg | 7.30 (7.29 to 7.30) | 85.4 (85.4 to 85.4) | 18.4 (18.4 to 18.5) | 16.5 (16.5 to 16.6) | 1.32 (1.32 to 1.33) | 4.0 (4.0 to 4.0) |
| Dabigatran, 110 mg | 7.09 (7.09 to 7.10) | 85.2 (85.2 to 85.2) | 14.1 (14.1 to 14.2) | 21.9 (21.9 to 22.0) | 1.77 (1.76 to 1.77) | 3.0 (3.0 to 3.0) |
| Edoxaban, 60 mg | 7.28 (7.28 to 7.29) | 85.4 (85.4 to 85.4) | 13.8 (13.8 to 13.9) | 23.6 (23.6 to 29.3) | 1.91 (1.90 to 1.91) | 2.9 (2.9 to 2.9) |
| Rivaroxaban, 20 mg | 7.30 (7.29 to 7.31) | 85.4 (85.4 to 85.4) | 14.1 (14.1 to 14.3) | 29.2 (29.2 to 29.3) | 2.36 (2.35 to 2.37) | 3.0 (3.0 to 3.0) |
| Dabigatran, 150 mg | 6.91 (6.90 to 6.92) | 85.0 (84.9 to 85.0) | 9.8 (9.7 to 9.8) | 42.7 (42.5 to 43.0) | 3.45 (3.43 to 3.47) | 2.3 (2.2 to 2.3) |
↵* Not adjusted for utility.